British F2G Biotech bags €24mThe European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd €24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF). more ➔
Sugar replacement slows cancer growthResearchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose. more ➔
Epigenetic drugs can increase tumour malig...Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors. more ➔
Forbion leads €40m financing in Inflazom...Inflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners. more ➔
EC advisors call for update of GM legislat...The EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing. more ➔
Boehringer and Epizyme enter US$300m dealBoehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase famil … more ➔
Breakthrough in restless legs syndromeResearchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome. more ➔
SOBI and AstraZeneca in US$2bn+ deal on RS...AstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish … more ➔
Amal bags €21.2m financingSwiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing. more ➔
Antibiotic resistance spreading across Eur...Antimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report. more ➔
